EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-600-3497
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."
How were Epirus Biopharmaceuticals' earnings last quarter?
Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) released its quarterly earnings data on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.20) by $0.32. View Epirus Biopharmaceuticals' Earnings History.
Has Epirus Biopharmaceuticals been receiving favorable news coverage?
Press coverage about EPRSQ stock has trended somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epirus Biopharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Epirus Biopharmaceuticals' key competitors?
Some companies that are related to Epirus Biopharmaceuticals include Orexigen Therapeutics (OREXQ), Immune Pharmaceuticals (IMNP), Inspyr Therapeutics (NSPX), Poniard Pharmaceuticals (PARD), Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Auris Medical (EARS), Bioblast Pharma (ORPN), Bohai Pharmaceuticals Group (BOPH), CannTrust (CNTTF), Cardiome Pharma (CRME), Concordia International (CXRXD) and Concordia International (CXRX).
What other stocks do shareholders of Epirus Biopharmaceuticals own?
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Mr. Jeff Kagy, VP of HR & Admin.
- Jason Yap, Head of Global Regulatory Affairs and Sr. Director
- Dr. Louis Boon, Head of CLG, Bioassay & Process Devel.
- Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
- Dr. Bram Bout Ph.D., Head of Epirus (Netherlands) B.V.
How do I buy shares of Epirus Biopharmaceuticals?
Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epirus Biopharmaceuticals' stock price today?
One share of EPRSQ stock can currently be purchased for approximately $0.0016.
How big of a company is Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals has a market capitalization of $40,000.00.
What is Epirus Biopharmaceuticals' official website?
How can I contact Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]
MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
